Oncolytics Biotech, Inc. (ONCY)
0.8602
+0.02
(+2.40%)
USD |
NASDAQ |
Sep 02, 11:48
Oncolytics Biotech Research and Development Expense (Annual) : 13.31M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 13.31M |
| December 31, 2024 | 15.44M |
| December 31, 2023 | 13.12M |
| December 31, 2022 | 11.85M |
| December 31, 2021 | 10.31M |
| December 31, 2020 | 9.651M |
| December 31, 2019 | 8.153M |
| December 31, 2018 | 7.737M |
| December 31, 2017 | 7.286M |
| December 31, 2016 | 7.244M |
| December 31, 2015 | 7.546M |
| December 31, 2014 | 12.31M |
| December 31, 2013 | 18.02M |
| December 31, 2012 | 31.45M |
| Date | Value |
|---|---|
| December 31, 2011 | 23.46M |
| December 31, 2010 | 13.29M |
| December 31, 2009 | 10.18M |
| December 31, 2008 | 12.51M |
| December 31, 2007 | 11.54M |
| December 31, 2006 | 9.289M |
| December 31, 2005 | 7.682M |
| December 31, 2004 | 5.462M |
| December 31, 2003 | 2.367M |
| December 31, 2002 | 2.728M |
| December 31, 2001 | 3.304M |
| December 31, 2000 | 2.484M |
| December 31, 1999 | 0.3276M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Sangamo Therapeutics, Inc. | 112.67M |
| Sarepta Therapeutics, Inc. | 1.493B |
| Anixa Biosciences, Inc. | 5.071M |
| Vicapsys Life Sciences, Inc. | 0.0006M |